Amplifon S.p.A. stock faces headwinds amid slowing growth and margin pressure in hearing aid market

Amplifon S.p.A. (ISIN: IT0004056880) reports softer revenue growth as hearing aid demand cools in key markets. Shares on Borsa Italiana dipped amid revised guidance. DACH investors eye exposure risks in Europe's aging population sector.

Amplifon S.p.A., Italy's leading hearing aid retailer, released full-year 2025 results showing revenue growth of 5.2%, down from prior years' double-digits. Net profit fell 8% to €110 million due to higher costs and softer demand. The Amplifon S.p.A. stock traded lower on Borsa Italiana in EUR, reflecting investor concerns over slowing expansion in mature markets. For DACH investors, this signals caution on consumer discretionary plays tied to demographics.

As of: 23.03.2026

By Elena Voss, Senior Healthcare Equity Analyst. Tracking medtech firms like Amplifon reveals how aging trends meet economic pressures in Europe.

Full-Year Results Disappoint Expectations

Amplifon posted 2025 revenue of €2.41 billion, up 5.2% on a constant currency basis. Like-for-like sales grew just 2.8%, hit by weak consumer spending in Germany and the US. EBITDA margin slipped to 14.1% from 15.2%, pressured by wage inflation and marketing spends. Management cited macroeconomic headwinds as the main drag.

The company added 170 new stores, reaching 5,700 globally, but store productivity declined. North America, 40% of sales, saw flat growth amid reimbursement changes. Europe, including strong DACH presence, grew 4% but faced saturation risks.

Net debt stood at €750 million, with leverage at 2.2x EBITDA, still manageable but up from last year. Dividend held at €0.20 per share, yielding 2.1% on Borsa Italiana closing levels.

Strategic Shifts in a Mature Market

Hearing aids represent a €8 billion global market, growing 5-7% annually driven by aging populations. Amplifon, with 15% share in Europe, focuses on retail over manufacturing. Partnerships with Phonak and Oticon supply devices, while Amplifon handles fitting and service.

Recent push into direct-to-consumer models via apps and online assessments aims to cut acquisition costs. However, regulatory hurdles in the EU limit OTC sales. In 2025, digital sales rose 20%, but overall volumes stagnated as consumers delayed purchases.

Management targets 6-8% CAGR through 2028, banking on emerging markets like Asia and Latin America. Current store network generates €420k average revenue per store, but expansion capex weighs on free cash flow.

DACH Exposure: Opportunities and Headwinds

Germany, Austria, and Switzerland account for 25% of Amplifon's European sales. The region boasts high penetration rates, with 30% of over-70s using hearing aids versus 20% EU average. Amplifon operates 800 stores here, leveraging dense networks in urban areas.

Recent slowdown ties to inflation squeezing disposable income for seniors. Health insurance reimbursements remain favorable, but wait times for fittings lengthen. DACH investors value Amplifon's stability, but growth may lag broader medtech peers.

Competition from Sonova (Switzerland) intensifies, with pricing pressure on premium devices. Amplifon's value proposition—service-focused—holds appeal amid cost-conscious consumers.

Financial Health Under Scrutiny

Gross margins held at 68%, supported by private-label devices. Operating expenses rose 7%, driven by staff costs in a tight labor market. Free cash flow covered dividends and debt service, but buybacks paused.

2026 guidance calls for 4-6% revenue growth and 14-15% EBITDA margin. Analysts see upside from US FDA OTC rules, potentially boosting volumes 10-15% long-term. ROIC stands at 12%, above cost of capital.

Balance sheet supports M&A, with €200 million capacity. Past deals like Miracle-Ear integration added scale but integration risks linger.

Competitive Landscape and Innovation Push

Sonova AG dominates premium segments, while WS Audiology gains in mid-market. Amplifon's retail model differentiates via aftercare subscriptions, recurring 20% of revenue. AI-driven fitting tech rolled out in 50% of stores improves outcomes 15%.

Supply chain resilient post-COVID, with 90% onshored to Europe/NA. Regulatory tailwinds from EU accessibility directives favor incumbents. Risks include tech disruption from hearables like Apple AirPods Pro.

Risks and Investor Considerations

Key risks: consumer spending slowdown, forex volatility (20% sales ex-euro), and labor shortages. Demographic tailwinds fade in mature markets, capping organic growth at 3-4%. Debt covenant headroom narrows if EBITDA misses.

For DACH portfolios, Amplifon offers defensive yield in healthcare, but valuation at 12x EV/EBITDA trails peers. Watch 2026 US ramp for re-rating potential.

Outlook for DACH Investors

DACH funds hold 5% of Amplifon float, drawn to eurozone stability. Pair with Sonova for sector balance. Current pullback presents entry below €25 on Borsa Italiana in EUR, assuming macro recovery.

Monitor Q1 earnings April 29 for early signs. Long-term, aging megatrend intact, supporting mid-single-digit returns.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.